Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment

PAEC features may be explained by the altered genes and their networks affecting tissue architecture although not involved in endometrial cancer signaling pathways, and thus, treatment with mifepristone at this dosage does not show any adverse effect at endometrial level.